Spelling suggestions: "subject:"amyloidbeta protein"" "subject:"amyloidbeta42 protein""
51 |
The inheritance of loss Caspase 6 activity and effect in human naurons caused by familial Alzheimer's Disease associated mutants /Sivananthan, Saskia Nikali, January 1900 (has links)
Thesis (M.Sc.). / Written for the Dept. of Neurology and Neurosurgery. Title from title page of PDF (viewed 2009/08/07). Includes bibliographical references.
|
52 |
Studies of regulated membrane trafficking /Cohen, Alona. January 2008 (has links)
Thesis (Ph. D.)--Cornell University, August, 2008. / Vita. Includes bibliographical references (leaves 164-175).
|
53 |
Structure-based design of peptides with modified backbones that inhibit beta-amyloid fibrillogenesis /Gordon, David Jon. January 2002 (has links)
Thesis (Ph. D.)--University of Chicago, Pritzker School of Medicine, Department of Biochemistry and Molecular Biology, June 2002. / Includes bibliographical references. Also available on the Internet.
|
54 |
Consequences of the interaction of amyloid beta with amyloid binding alcohol dehydrogenase and the receptor for advanced glycation end products /Ren, Yimin. January 2008 (has links)
Thesis (Ph.D.) - University of St Andrews, May 2008.
|
55 |
The impact of apolipoprotein E on cholesterol metabolism and Alzheimer's diseaseMann, Karen M. January 2005 (has links)
Thesis (Ph. D.)--Case Western Reserve University, 2005. / [School of Medicine] Department of Genetics. Includes bibliographical references. Available online via OhioLINK's ETD Center.
|
56 |
Tacrine, trolox and tryptoline as lead compounds for the design and synthesis of multi-target drugs for Alzheimer's disease therapyTeponnou, Gerard A. Kenfack January 2016 (has links)
Magister Pharmaceuticae - MPharm / The cascade of neurotoxic events involved in the pathogenesis of Alzheimer's disease may explain the inefficacy of currently available treatment based on acetylcholinesterase inhibitors (AChEI - donepezil, galantamine, rivastigmine) and N-methyl-D-aspartate (NMDA) antagonists (memantine). These drugs were designed based on the "one-moleculeone- target" paradigm and only address a single target. Conversely, the multi-target drug design strategy increasingly gains recognition. Based on the versatile biological activities of tacrine, trolox and β-carboline derivatives, the attention they have received as lead structures for the design of multifunctional drugs for the treatment of Alzheimer's disease, and the topology of the active site of AChE, we have designed tacrine-trolox and tacrine-tryptoline hybrids with various linker chain lengths. The aim with these hybrids was to provide additive or synergistic therapeutic effects that might help overcome the limitation of current anti Alzheimer's disease drugs. All synthesized compounds were designed from lead structures (tacrine, tryptoline and trolox) to obtain cholinesterase (ChE) multisite binders and multifunctional AD agents. The study was rationalized by docking all structures in the active site of TcAChE using Molecular Operating Environment (MOE) software before proceeding with the synthesis. ChE inhibition was assessed in a UV enzyme inhibition assay using Ellman's method. Antioxidant activities were assessed using the 2, 2-diphenyl-1-picrylhydrazyl (DPPH.) absorbance assay. The hybrids containing the trolox moiety (compounds 8a-e) showed moderate to high AChE inhibitory activity in the nano to micro molar range (IC₅₀: 17.37 - 2200 nM), BuChE inhibition was observed in the same range (IC₅₀: 3.16 – 128.82 nM), and free radical scavenging activities in micro molar range (IC50: 11.48 – 49.23 µM). These are comparable or slightly higher than their reference compounds donepezil (AChE IC₅₀ = 220 nM), tacrine (BuChE IC₅₀: 14.12 nM), and trolox (DPPH IC₅₀: 17.57 µM). The hybrids with longer linker chain lengths, 6 and 8 carbons (8d and 8e), showed better ChE inhibitory activity than the shorter ones, 2, 3, and 4 carbons (8a-c respectively). This correlates well with literature. Free radical scavenging activities, however, seems not to be significantly affected by varying linker chain lengths. The hybrid compound (14) containing the tryptoline moiety linked with a 7 carbon spacer displayed the best AChE and BuChE inhibitory activity (IC₅₀ = 17.37 and 3.16 nM) but poor free radical scavenging activity. Novel anti-Alzheimer's disease drugs
with multi-target neuroprotective activities were thus obtained and hybrid molecules that exhibit good ChE inhibition (8d, 8e and 14) and anti-oxidant (8d and 8e) activity were identified as suitable candidates for further investigation. / National Research Foundation (NRF)
|
57 |
The effects of a human b-amyloid gene on learning and memory in transgenic mice /Tirado Santiago, Giovanni January 1994 (has links)
No description available.
|
58 |
The Alzheimer's disease beta amyloid protein precursor: Analysis of the carboxyl terminus of its soluble derivativesPasternack, Jennifer Martine January 1992 (has links)
No description available.
|
59 |
Investigation of the role of engulfment adaptor protein 1 (GULP1) in amyloid precursor protein (APP) processing. / CUHK electronic theses & dissertations collectionJanuary 2013 (has links)
Chiu, Wai Yin Vivien. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2013. / Includes bibliographical references (leaves 151-162). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Abstracts also in Chinese.
|
60 |
Monocytes as gene therapy vectors for the treatment of Alzheimer's disease /Lebson, Lori Ann. January 2008 (has links)
Dissertation (Ph.D.)--University of South Florida, 2008. / Includes vita. Includes bibliographical references.
|
Page generated in 0.0511 seconds